Clinical trial INCAGN1876-201
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Incyte Corporate |
| EudraCT Identifier | 2016-004989-25 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03126110 |
| Inclusion criteria | second line RECIST 1.1 Biopsy |
| Last update |